Purpose: Nona-D-arginine (D9R) amide suppressed interleukin 1b production during Pseudomonas aeruginosa corneal infection. The purpose of this study was to determine the cellular disposition of D9R and its effect on other inflammatory mediators induced by infection.
Results: Eyes treated with D9R had significantly lower disease scores (P # 0.001) and fewer CFUs (P # 0.01) than those in PBStreated eyes. No corneal cytokines were detected in any D9R-treated eyes. In contrast, beginning at 12 hours postinfection, increasing amounts of tumor necrosis factor alpha, interleukin 10, and granulocyte-macrophage colony-stimulating factor were detectible in corneas of PBS-treated eyes. Within 60 minutes, D9R accumulated in the cell nucleus and nucleolus and remained for over 24 hours.
Conclusion: D9R reduces the severity of P. aeruginosa ocular infection in part by reducing bacterial burden and in part by controlling a destructive proinflammatory response. D9R might be a useful alternative to steroids in treating other inflammation-mediated pathologies of the eye.
Key Words: nona-D-arginine, Pseudomonas aeruginosa, cytokine, keratitis (Cornea 2010;29:1308-1314) P seudomonas aeruginosa is a common cause of corneal infections, especially in users of soft extended wear contact lenses. 1 The organism can be readily cultured from the lenses themselves and from contact lens cases and lens care solutions.
2 P. aeruginosa corneal ulcers are considered an ophthalmic emergency given the rapid and significant loss of corneal epithelium and stromal tissue. Even with effective antibacterial therapy, corneal perforation can still occur within 24-48 hours. 3 Tissue destruction in P. aeruginosa corneal disease is because of the host responding to infection with an acute inflammatory response [a cytokine storm accompanied by an influx of predominately polymorphonuclear leukocytes (PMN)] and by toxic products secreted by the bacteria.
In an earlier study, 4 nona-D-arginine (D9R) amide topically applied at a concentration of 100 mM significantly reduced corneal damage in a mouse model of P. aeruginosa ocular disease. When combined with ciprofloxacin, a true clinical cure was achieved, that is, elimination of viable P. aeruginosa from the infected eye with minimal damage to the cornea. It also significantly reduced the proinflammatory cytokine interleukin (IL) 1b response in infected corneas, an event that likely contributed to a better disease outcome.
In this study, D9R administered topically without a concomitant antibacterial drug significantly reduced corneal pathology and bacterial burden associated with an ocular P. aeruginosa infection. As with IL-1b, treatment with D9R significantly reduced corneal concentrations of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-a) and granulocyte-macrophage colony-stimulating factor (GM-CSF). When applied to human corneal epithelial cells and macrophages in vitro, labeled D9R translocated to the nucleus and nucleolus of cells where it remained for over 24 hours.
MATERIALS AND METHODS

Bacterial and Mouse Models of Infection
P. aeruginosa strain PAO1 was obtained from the Pseudomonas Genetic Stock Center, East Carolina University Brody School of Medicine, Greenville, NC. Six-to eightweek-old, male and female, black Swiss mice were purchased from Taconic Farms, Inc (Germantown, NY). Mice were maintained in accordance with institutional guidelines and tenets of the Association for Research in Vision and Ophthalmology Resolution on the use of animals in ophthalmic and vision research.
To prepare an inoculum, a bacterial colony was picked from a Pseudomonas isolation agar (Difco; BD Diagnostics, Sparks, MD) plate and inoculated into 10 mL of Luria-Bertani broth (Sigma-Aldrich, St. Louis, MO). Cultures were grown at 37°C on a rotary shaker at 160 rpm for 18 hours. The overnight cultures were then subcultured into 10 mL of fresh LuriaBertani broth, and the bacteria were grown to logarithmic phase to an optical density of 0.2 [2 3 10 8 colony-forming unit (CFU)/mL] at 600 nm. The inoculum was centrifuged at 5000g for 15 minutes and resuspended in phosphate-buffered saline (PBS, pH 7.4) (GIBCO; Invitrogen, Grand Island, NY) to a concentration of 2 3 10 8 CFU/mL. Mice were infected essentially as described by Kwon and Hazlett. 5 In brief, mice were anesthetized with ketamine (200 mg/kg; Vedco, St Joseph, MO) and xylazine (10 mg/kg; NLS Animal Health, Pittsburg, PA) intraperitoneally. The corneas of right eyes were scarified by making 3 parallel incisions (1 mm deep) with a 21G needle. These incisions did not penetrate beyond the superficial stroma. Wounded corneas were then topically inoculated with 5 mL (1 3 10 6 CFU) of P. aeruginosa in PBS.
Treatment With Nona-D-Arginine Amide D9R (American Peptide, Co, Sunnyvale, CA) was dissolved in sterile, distilled, deionized water at a stock concentration of 1 mM and stored at 280°C. D9R was used at a concentration of 100 mM by diluting the stock solution in PBS. Immediately after infection with P. aeruginosa PAO1, eyes received a 5-mL drop of either PBS or 100 mM D9R. Application of PBS or D9R continued hourly for 5 hours (total of 6 drops per infected eye). All eyes were assessed for disease progression at 6, 12, and 24 hours postinfection (PI). At least 5 mice were infected per treatment group per time point, and all experiments were repeated at least 2 times (ie, N $ 15 eyes per treatment group per time point).
Slit-Lamp Examination
At 6, 12, and 24 hours PI, the ocular response to bacterial challenge and treatment was examined and photographed with a slit-lamp microscope (Topcon Biomicroscope SL-D7; Paramus, NJ). Disease was scored in a masked fashion. The scoring system employed was essentially the one described by Hazlett et al 6 with some minor modifications: 0 = clear or normal cornea, +1 = light to dense opacity at wound site, +2 = dense opacity fully covering the pupil, +3 = dense opacity fully covering the anterior segment, and +4 = corneal perforation or phthisis bulbi (ie, shrunken eye).
Determination of Viable Bacteria Per Eye
After slit-lamp examination and scoring, mice were euthanized and the eyes were enucleated. For CFU determination, individual whole eyes were homogenized in 1 mL of sterile PBS. Serial 10-fold dilutions of homogenate were made (1:10 dilution), 0.1 mL was plated onto Pseudomonas isolation agar in duplicate, and the plates were incubated for 24 hours at 37°C. Numbers of viable bacteria in the eyes are expressed as the mean log 10 number of CFU of bacteria 6 standard error of the mean (SEM).
Quantitation of Corneal Cytokine Concentrations
Corneas were dissected from infected and uninfected enucleated eyes at 6, 12, and 24 hours PI and individually frozen at 280°C. Excised corneas were thawed on ice and individually homogenized in 60 mL of PBS with 1% Triton X-100 using sterile tissue homogenizers. Homogenates were centrifuged at 5000g at 4°C for 15 minutes. Supernatants were immediately frozen at 280°C until assayed. TNF-a, interferon gamma (IFN) g, IL-10, and GM-CSF in the homogenates were quantified using a Bio-Plex assay (Bio-Rad Laboratories, Hercules, CA) per the manufacturer's instructions. The sensitivity of the assay is 10 pg/mL for each of the cytokines. A value of zero was assigned to samples that were below the range of detection. Corneal cytokine concentrations are expressed as picograms per milliliter.
Cellular Localization of D9R
D9R labeled with the red fluorescent dye 5-carboxytetramethylrhodamine (TAMRA-D9R; American Peptide, Co) was dissolved in sterile, distilled, deionized water at a stock concentration of 1 mM and stored at 280°C. TAMRA-D9R was used at a concentration of 5 mM by diluting the stock solution with PBS (GIBCO; Invitrogen). Hoechst 33342 (10 mg/mL solution in water; Sigma), a cell nucleus stain, was used at a concentration of 200 mg/mL in distilled water for cell culture assays.
Immortalized human corneal epithelial cells (HCEC) 7 were seeded in 2-well Lab-Tek II chamber slides (Nunc, Rochester, NY) in serum-free keratinocyte growth medium (KGM; Lonza Biologics, Inc, Portsmouth, NH) for 24 hours at 37°C. After the cells reached approximately 60% confluence, 5 mL of 5 mM TAMRA-D9R was added to slides, which were then incubated at 37°C for 1 hour. Cells were then washed with PBS to remove excess TAMRA-D9R, and then fresh medium without TAMRA-D9R was added. Cells were incubated for further 1, 3, 6, 24, or 48 hours. At the end of each time point, the medium was removed and the cells were gently washed with PBS 3 times. Cells were then stained with the blue nuclear dye, Hoechst 33342 (Sigma), for 45 seconds and washed 3 times with PBS. The localization of TAMRA-D9R in live cells was then visualized and photographed with a fluorescence microscope (Zeiss, Thornwood, NY) at a magnification of 3100. Because macrophages play an important role in determining the pathological consequences (corneas of ''susceptible'' mice perforate vs. ''resistant'' mice that clear infection without loss of the eye) of a P. aeruginosa corneal infection in mice, 8 a macrophage-like cell line (RAW 264.7) was also used in these experiments. 9 These cells were obtained from the American Type Culture Collection (ATCC TIB-71; Manassas, VA) and grown in 2-well Lab-Tek II chamber slides in Dulbecco minimum essential medium (GIBCO; Invitrogen). The localization of TAMRA-D9R was visualized in live RAW 264.7 cells as described for HCEC.
Effect of D9R on Transcription
The localization of D9R within the nucleus and nucleolus is reminiscent of 2 arginine-rich viral activators of transcription: Epstein-Barr nuclear antigen 1 (EBNA1) and human immunodeficiency virus type 1 trans-activator of transcription (HIV-TAT). The arginine-rich regions of EBNA1 and HIV-TAT are found in DNA-binding motifs known as AT-hooks. These AT-hook motifs are essential for EBNA1 and HIV-TAT to function as transcriptional activators. This experiment was performed to determine if D9R could be regulating transcription of cytokines and other mediators of inflammation by preventing proteins with AT-hooks (such as EBNA1 or HIV-TAT) from binding to DNA.
Using a luciferase-based assay essentially as described by Aras et al 10 and Singh et al, 11 the effects of D9R on transcription were examined. In brief, herpes virus-free human cervical carcinoma C33a cells were either cotransfected with an EBNA1 expression vector and a reporter plasmid with a luciferase gene under the control of a natural EBNA1 (Cp) promoter or with an HIV-TAT expression vector and a reporter plasmid with a HIV-TAR (trans-activating response region) luciferase fusion under the control of a herpes simplex thymidine kinase promoter. Thus, cotransfected cells constitutively express luciferase and produce a quantifiable amount of luminescence. Interference with binding of EBNA1 or HIV-TAR by D9R would result in less luciferase production and a subsequent decrease in luminescence.
Six hours after transfection, cells were split onto a 12-well plate and individual wells remained untreated (0-mM D9R) or were treated with 10-, 30-, and 100-mM D9R. After 24-hour incubation, cells were harvested, counted twice in a Coulter counter pelleted and lysed using reporter lysis buffer (Promega, Madison, WI), and analyzed for luciferase expression using a Zylux FB15 tube luminometer (Zylux, Corp, Huntsville, AL). This experiment was repeated twice, and results were expressed as the mean relative expression of luciferase 6 SD.
Statistical Analyses
All analyses were performed using GraphPad Prism v4.03 (GraphPad Software, San Diego, CA). Mean disease scores between D9R-and PBS-treated groups (N $ 15 per treatment group per time point) were compared using 1-way analysis of variance. All other analyses were performed using an unpaired Student t test. A probability value of P # 0.05 was considered statistically significant.
RESULTS
D9R Reduces Ocular Pathology and Viable CFU Per Eye
Mean (6SEM) slit-lamp examination scores for P. aeruginosa-infected eyes assessed at 6, 12, and 24 hours PI are shown in Table 1 . At 6 hours PI, there were no observable signs of ocular disease and all eyes were given a score of 0. By 12 hours PI, eyes treated with PBS had mild opacities partially covering the pupil (+2), whereas eyes receiving D9R treatment did not show any signs of infection (0). At 24 hours PI, all eyes treated with PBS had dense corneal opacities covering the entire eye (+3). In contrast, D9R-treated eyes had significantly lower disease scores (P # 0.0001) with opacities limited to the wound site (+1).
The number of viable bacteria present in eyes at 6, 12, and 24 hours PI, expressed as the mean log 10 CFU (6SEM) per eye, is shown in Figure 1 . As expected, the numbers of bacteria in infected eyes, regardless of treatment, increased over time. However, eyes that were treated with 100-mM D9R had significantly fewer CFU per eye (P # 0.01) when compared with PBS-treated eyes at all time points examined.
D9R Suppresses Cytokine Expression
The concentrations of corneal TNF-a, IFN-g, IL-10, and GM-CSF at 6, 12, and 24 hours PI, expressed as mean (6SEM) picograms of cytokine per milliliter of corneal homogenate, are shown in Table 2 . No cytokines were detected in uninfected untreated corneas. Similarly, any concentrations of TNF-a, IFN-g, IL-10, and GM-CSF were below the limits of detection (10 pg/mL) at all time points tested in corneas treated with D9R. However, by 12 hours PI, concentrations of TNF-a, IL-10, and GM-CSF were detectable in corneas treated with PBS. Concentrations of these 3 cytokines continued to increase by 24 hours PI, most noticeably with TNFa. IFN-g was not detected in any of the infected corneas, regardless of the time PI or treatment with PBS or D9R.
D9R Rapidly Localizes in the Nucleus and Nucleolus of Cells
TAMRA-D9R localized to the nucleus and nucleolus of HCEC and macrophage-like RAW 264.7 cells within an hour. FIGURE 1. Viable bacteria in mouse eyes at 6, 12, and 24 hours PI. Corneas were scarified with a 21G needle and topically inoculated with 1 3 10 6 CFU of P. aeruginosa PAO1 followed by treatment with PBS or 100-mM D9R. Eyes were enucleated at 6, 12, and 24 hours PI and processed for determining log 10 CFU per eye. Eyes that were treated with 100-mM D9R had significantly lower CFU (*P # 0.01) compared with that of PBS-treated eyes.
The labeled peptide remained in the nuclei and nucleoli for over 24 hours after incubation. The nuclear localization was confirmed by costaining cells with Hoechst dye.
As shown in Figure 2 , at 6 hours PI, both TAMRA-D9R and the Hoechst dye colocalized to the nucleus and appeared to concentrate in the nucleolus. Staining of RAW 264.7 cells is shown in Figure 3 . By 48 hours PI, cells had undergone mitosis and D9R could not be located in the nucleus (data not shown).
D9R Inhibits Transcription
As shown in Table 3 , exposure to increasing concentrations of D9R resulted in incremental decreases in luminescence. Treatment of cotransfected C33a cells with 100-mM D9R resulted in luminescence being decreased by approximately 50%-65% relative to untreated cells. These findings suggest that D9R was inhibiting transcription of the reporter gene luciferase, perhaps by competing with the arginine-rich AT-hook regions of the transcriptional activators EBNA1 and HIV-TAT.
DISCUSSION
The host immune response is critical in determining the outcome of P. aeruginosa keratitis. The primary immune cells involved in controlling bacterial replication in the cornea are PMNs. Rapid recruitment of PMNs into the infected cornea is essential for bacterial killing, but persistence of these cells leads to stromal scarring and possible perforation. 12 The recruitment of PMNs from blood vessels into the inflamed cornea is a highly orchestrated process that involves a wide array of inflammatory mediators.
Several studies have shown that overexpression of proinflammatory cytokines and chemokines leads to a vigorous immune response that contributes to corneal damage. 3, 12 Studies by Rudner et al 13 indicate that significantly greater amounts of IL-1b are present in infected corneas of susceptible (C57BL/6; cornea is destroyed) versus resistant (BALB/c; cornea is scarred but otherwise intact) mice and that excess amounts of this cytokine can result in poor disease outcome. IL-1b upregulates macrophage inflammatory protein 2, leading to prolonged neutrophil recruitment into the cornea of susceptible mice. A timelier downregulation of IL-1b in Cytokines are expressed as mean picograms cytokine per milliliters 6 SEM. Concentrations below the limit of detection (10 pg/mL) were assigned a value of 0.
FIGURE 2. Localization of D9R in HCEC 6 hours after incubation. HCECs were exposed to 5-carboxytetramethylrhodamine (TAMRA-D9R) for 1 hour, washed with PBS, and then incubated for further 6 hours. Cells were also briefly exposed to the blue nuclear dye, D9R Suppresses Corneal Cytokines resistant mice allows for bacterial clearance with much less corneal destruction. When determined using the same experimental conditions and method of assay as in this study, D9R (100 mM) significantly reduced the production of IL-1b in P. aeruginosa-infected corneas at 6, 12, and 24 hours PI. 4 Similar to the reduction of IL-1b, treatment with 100-mM D9R reduced the concentrations of TNF-a, IFN-g, IL-10, and GM-CSF below the limits of detection (10 pg/mL) of the Bio-Plex (Bio-Rad) assay. GM-CSF was detected in an inflamed P. aeruginosa-infected cornea treated with PBS 12 hours PI, and the concentration of this cytokine practically doubled by 24 hours PI. This cytokine functions as a growth factor involved in survival of PMNs. HCEC strongly express GM-CSF in response to heat-killed P. aeruginosa. 14, 15 In this study, IL-10 was expressed at 12-hour PI in PBStreated corneas, and this expression increased approximately 10-fold by 24-hour PI. No IL-10 was detected in any cornea treated with 100-mM D9R. To date, only 2 investigators have specifically looked at the role of IL-10, a Th2 cytokine, in P. aeruginosa corneal disease, and their results are somewhat contradictory. Discrepancies between the 2 studies are likely because of differences in study design. Cole et al 15 infected corneas of IL-10 knockout mice and their wild-type C57BL/6 controls with P. aeruginosa strains 6206 and 6294 and observed a significant reduction of bacterial burden and neutrophil numbers in corneas of knockout mice compared with controls. Accompanying this reduction in bacteria and neutrophils was a significant amount of corneal neovascularization. Hazlett et al 16 treated wild-type C57BL/6 mice infected with P. aeruginosa strain ATCC 19660 with spantide I (a substance P antagonist) and reported enhanced corneal production of IL-10. Associated with increased IL-10 production was a significant reduction in corneal perforation and a better disease outcome. Corneal neovascularization in spantide I-treated mice was not assessed.
Blood vessel growth into the avascular cornea compromises its transparency and thus affects vision. Others have shown reduced neovascularization in corneas of IL-10 knockout mice with herpes simplex virus-1 stromal keratitis 17 or suture-induced inflammation. 18 In the current study, the lack of corneal IL-10 in 100-mM D9R-treated mice at 24-hour PI cannot be definitively associated with a reduction in neovascularization because this pathology is not observed in P. aeruginosa-infected corneas until 7 days PI. 4 In addition to GM-CSF and IL-10, TNF-a was significantly upregulated in an infected PBS-treated cornea. TNF-a plays an essential role in the activation and recruitment of PMNs into the cornea after infection. 19 Interestingly, there was no IFN-g detected from any of the corneas sampled. IFN-g is an important cytokine in the immunopathogenesis of P. aeruginosa corneal disease. 12 It can be detected by enzyme-linked immunosorbent assay as early as 6-hour PI, 20 although most studies examine IFN-g production by reverse transcription polymerase chain reaction. The apparent absence of IFN-g expression in this study could be explained by differences in detection methods (Bio-Plex vs. enzyme-linked immunosorbent assay vs. reverse transcription polymerase chain reaction), in strains of P. aeruginosa employed, or in which strain of mouse was infected.
The mechanisms by which D9R downregulates the proinflammatory cytokine response are unclear. The most potent inducer of inflammation in Gram-negative bacteria is lipopolysaccharide (LPS). Cyclic cationic peptides such as polymyxin B inhibit the biological activity of LPS by binding to the lipid A moiety.
21 D9R is positively charged; therefore, the peptide might bind to polyanionic LPS and prevent its interaction with lipid-binding protein, thereby blocking induction of proinflammatory cytokine production. Interaction of polycationic D9R with LPS might also perturb the barrier function of the outer membrane much like polymyxin B and result in the death of P. aeruginosa.
Another possible mechanism that D9R might affect cytokine production involves binding of D9R with P. aeruginosa unmethylated CpG DNA. CpG DNA is a potent inducer of proinflammatory cytokines through toll-like receptor (TLR)-9 signaling. Huang et al 22 have shown that injsection of P. aeruginosa CpG DNA in C57/B6 mice led to increased expression of TLR-9, elevated proinflammatory cytokine production, and rapid influx of PMNs into the corneas of susceptible mice. Downregulation of TLR-9 signaling by injection of TLR-9-specific small interfering RNA before infection significantly reduced proinflammatory cytokine induction and prevented corneal perforation in these mice. Lingnau et al 23 demonstrated that poly-L-arginine bound to the oligonucleotides containing CpG DNA and prevented the systemic production of proinflammatory cytokines in mice. Taken together, polycationic D9R might bind to anionic CpG DNA of P. aeruginosa and prevent it's interaction with TLR-9, thereby downregulating proinflammatory cytokine production and PMN persistence in infected corneas.
D9R labeled with 5-carboxy-tetramethylrhodamine (TAMRA-D9R) was used to study the peptide's localization in HCECs and RAW 264.7 cells. TAMRA-D9R was efficiently taken up by these cells within an hour and localized to the nucleus and the nucleolus. These observations are in accordance with the results obtained by Futaki et al, 24 who demonstrated that arginine-rich peptides were capable of translocating into RAW 264.7 cells and localize to the nucleus and the nucleolus after 3 hours of incubation. Futaki et al 24 also established that the chain length of these peptides was a major factor in deciding uptake by these cells. Only polyarginines with chain lengths at or above 6 arginine residues were efficiently translocated to the nucleus. However, increasing the chain lengths to 16 arginine residues led to their accumulation on cell membranes. Small cationic peptides that have the ability to cross lipid bilayers have been termed ''protein transduction domains,'' and nona-L-arginine was found to be the most efficacious protein transduction domain to date. 25 There is a biological precedent for arginine-rich peptides to expediently translocate across cell membranes, accumulate in the nucleus, and subsequently affect gene expression. Studies 26 with HIV-TAT showed that purified trans-activator of transcription was efficiently taken up and directed to the nucleus of HeLa cells and was able to transactivate HIV-1 promoters. The arginine-rich basic region (amino acids 49-58) of trans-activator of transcription is essential for uptake and nuclear localization because mutation of arginine residues abolished uptake. 27 Portions of HIV-TAT comprised only this basic region were efficiently translocated and localized to the nucleus of cells. Likewise, the transcription factor EBNA1 contains glycine-arginine-rich motifs that bind to AT-rich regions of DNA. 28 The arginine-rich AT-hook motifs of high-mobility group (HMG) eukaryotic chromosomal proteins regulate gene expression by binding to the minor groove of AT-rich regions of DNA. 29 On the basis of these observations, it was hypothesized that D9R might be binding to AT-rich DNA similar to HMG proteins and thus regulate expression of proinflammatory cytokines and chemokines. D9R was able to significantly inhibit transcription of a reporter gene (luciferase) that required transactivation by EBNA1 or HIV-TAT (2 viral homologues of HMG proteins) in a concentration-dependent manner. At a concentration of 100 mM, D9R was able to reduce luminescence of control cells by 50%-65% (cells that were transfected with the luciferase reporter gene and incubated with the culture medium alone without any exposure to D9R). The finding that D9R concentrated in the nucleolus (site of ribosomal RNA synthesis) suggests that the peptide is able to efficiently interact with other anionic targets such as RNA within the cell. Further studies are required to determine whether D9R binds to specific RNA targets.
The current study also showed that D9R was detected in HCECs and RAW 264.7 cells for upto 24 hours. By 48-hour postincubation, none of the peptide was observed in the cell. Because D-peptides are resistant to naturally occurring proteases, 30 the peptide may have been diluted out because of cell proliferation to a point where it could not be visualized.
In conclusion, D9R would be a useful addition to the current regimen of topical antibiotics for the treatment of P. aeruginosa keratitis because of its antiinflammatory and antibacterial properties. This peptide might also be useful in treating other ocular diseases where the host inflammatory response is a significant contributor to pathology.
